SCHEMBL3608666

SCHEMBL3608666

NC(=O)c1cc2cc(N)ccc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 2/20 0.56
CYP2A6 P11509 1/20 0.52
KEAP1 Q14145 1/20 0.52
PDGFRB P09619 3/20 0.49
FLT3 P36888 3/20 0.49
ABL1 P00519 1/20 0.49
KIT P10721 1/20 0.49
BCR P11274 1/20 0.49
SMAD3 P84022 1/20 0.47
MMP2 P08253 1/20 0.47
MMP13 P45452 1/20 0.47
NGFR P08138 1/20 0.46
KDM4E B2RXH2 2/20 0.46
HPGD P15428 2/20 0.46
HSD17B10 Q99714 2/20 0.46
F7 P08709 1/20 0.46
F3 P13726 1/20 0.46
PIN1 Q13526 1/20 0.46
PDPK1 O15530 1/20 0.46
ALDH1A1 P00352 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19329742 0.85 HRH4 (0.56) HRH4FLT3NGFRKDM4EHPGD
SCHEMBL1333512 0.85 SMAD3 (0.66) HRH4CYP2A6KEAP1PDGFRBFLT3
SCHEMBL12862877 0.84 HRH4 (0.58) HRH4CYP2A6KEAP1PDGFRBFLT3
SCHEMBL3282981 0.81 FLT3 (0.73) HRH4PDGFRBFLT3ABL1KIT
SCHEMBL1651087 0.81 MMP2 (0.66) HRH4PDGFRBFLT3ABL1KIT
SCHEMBL12086506 0.80 HRH4 (0.55) HRH4PDGFRBFLT3ABL1KIT
SCHEMBL764543 0.80 F7 (0.72) HRH4FLT3F7F3DAO
SCHEMBL250527 0.80 KDM4E (0.72) HRH4FLT3KDM4EHPGDHSD17B10
SCHEMBL1156450 0.80 FLT3 (0.57) HRH4PDGFRBFLT3ABL1KIT
SCHEMBL11960184 0.80 PIN1 (0.72) HRH4PDGFRBFLT3MMP2MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4676912-A2 COMPOUNDS, COMPOSITIONS, AND METHOD OF INHIBITING TAU PROTEIN AND ALPHA-SYNUCLEIN AGGREGATION Purdue Research Foundation (US) 2026-01-14 EP disclosed
WO-2024206127-A2 COMPOUNDS, COMPOSITIONS, AND METHOD OF INHIBITING TAU PROTEIN AND ALPHA-SYNUCLEIN AGGREGATION PURDUE RESEARCH FOUNDATION (US) 2024-10-03 WO disclosed
US-7723325-B2 5-amido-indole-2-carboxamide derivatives HOFFMAN-LA ROCHE INC. (US) 2010-05-25 US disclosed
US-7601711-B2 Such as [5-(4-cyclopentyl-piperazine-1-carbonyl)-1H-indol-2-yl]-morpholin-4-yl-methanone; histamine H3-antagonists HOFFMANN-LA ROCHE INC. (US) 2009-10-13 US disclosed
CN-101421235-A 5-amido-2-amide indoles HOFFMANN LA ROCHE (CH) 2009-04-29 CN disclosed
CN-101421235-A 5-amido-2-amide indoles HOFFMANN LA ROCHE (CH) 2009-04-29 CN disclosed
US-20070244125-A1 5-amido-indole-2-carboxamide derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244125-A1 5-amido-indole-2-carboxamide derivatives HRH4, HRH3, CNR2 HRH4 1/4885CYP2A6 571/4885KEAP1 3614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.